- Home
- TVRD vs SGMT Comparison
TVRD vs SGMT Comparison
Compare TVRD & SGMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVRD
- SGMT
- Stock Information
- Founded
- TVRD 2017
- SGMT 2006
- Country
- TVRD United States
- SGMT United States
- Employees
- TVRD N/A
- SGMT N/A
- Industry
- TVRD Biotechnology: Pharmaceutical Preparations
- SGMT
- Sector
- TVRD Health Care
- SGMT
- Exchange
- TVRD Nasdaq
- SGMT Nasdaq
- Market Cap
- TVRD 246.5M
- SGMT 230.3M
- IPO Year
- TVRD N/A
- SGMT 2023
- Fundamental
- Price
- TVRD $29.92
- SGMT $7.51
- Analyst Decision
- TVRD Strong Buy
- SGMT Strong Buy
- Analyst Count
- TVRD 5
- SGMT 7
- Target Price
- TVRD $59.20
- SGMT $26.57
- AVG Volume (30 Days)
- TVRD 23.2K
- SGMT 635.5K
- Earning Date
- TVRD 08-14-2025
- SGMT 08-13-2025
- Dividend Yield
- TVRD N/A
- SGMT N/A
- EPS Growth
- TVRD N/A
- SGMT N/A
- EPS
- TVRD N/A
- SGMT N/A
- Revenue
- TVRD N/A
- SGMT N/A
- Revenue This Year
- TVRD N/A
- SGMT N/A
- Revenue Next Year
- TVRD N/A
- SGMT N/A
- P/E Ratio
- TVRD N/A
- SGMT N/A
- Revenue Growth
- TVRD N/A
- SGMT N/A
- 52 Week Low
- TVRD $8.13
- SGMT $1.73
- 52 Week High
- TVRD $34.31
- SGMT $11.41
- Technical
- Relative Strength Index (RSI)
- TVRD 65.43
- SGMT 43.71
- Support Level
- TVRD $22.91
- SGMT $6.97
- Resistance Level
- TVRD $31.54
- SGMT $7.86
- Average True Range (ATR)
- TVRD 1.65
- SGMT 0.63
- MACD
- TVRD 0.61
- SGMT -0.06
- Stochastic Oscillator
- TVRD 81.28
- SGMT 27.71
About TVRD Tvardi Therapeutics Inc. Common Stock
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.
About SGMT Sagimet Biosciences Inc. Series A
Sagimet Biosciences Inc is a clinical-stage biopharmaceutical company dedicated to developing a portfolio of in-house discovered, selective fatty acid synthase (FASN) inhibitors aimed at treating diseases that arise from dysfunctional lipid metabolism pathways. The company's drug candidate, denifanstat, is an oral, once-daily pill that serves as a selective FASN inhibitor under development for treating nonalcoholic steatohepatitis (NASH). The company functions as a single business segment, focusing on the development and commercialization of therapeutics for MASH and other diseases where FASN plays a pathogenic role.